Based on these data, we speculate that the protective effects of B2R-antagonism could potentially prevent the early stages of COVID-19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural airway damage and fibrotic changes. This evidence concerns the gene BDKRB2 and acute respiratory distress syndrome.